Illumina Inc (ILMN) Stock Analysis
$ILMN · HEALTHCARE · DIAGNOSTICS & RESEARCH
Illumina (ILMN), a DIAGNOSTICS & RESEARCH company, has a market capitalization of about $39.64B and trades at 47.0x trailing earnings.
Price
$262.54
Market cap
$39.64B
P/E ratio
47.0x
Dividend yield
—
About Illumina Inc
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
How StockWorthy values ILMN
StockWorthy forecasts Illumina Inc's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from ILMN's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See ILMN's Fair Value
Create a free account to view Illumina Inc's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.